CalAmp (Nasdaq: CAMP), an advanced technology solutions company, has signed a strategic collaboration with Cryoport (Nasdaq: CYRX) (Nasdaq: CYRXW), a temperature-controlled logistics company dedicated to the life sciences industry.
It was reported yesterday that the collaboration is aimed at developing a next generation condition monitoring system to further assure the security of global temperature controlled pharmaceutical shipments. This research and development collaboration is aimed at improving the protection and preservation of critical life science shipments, which demonstrates CalAmp's continued momentum in the supply chain visibility market and Cryoport's commitment to providing the most advanced best-in-class, data-driven solutions to its biopharmaceutical client base.
Along with CalAmp, Cryoport is exploring an advanced supply chain visibility service that will monitor, in real-time, environmental readings for regenerative medicine product shipments using Bluetooth sensor technology. If successful, the combination of the Cryoport Express Shippers and the Cryoportal Logistics Management Platform, coupled with CalAmp's new-to-market SC iOn Tag Bluetooth sensor technology and SC iOn Command platform, is to allow Cryoport to offer another advanced logistics solution that would pro-actively manage supply chain visibility across multi-mode global shipping routes.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering